TABLES:
Table I – Demographic and clinical characteristics of severe asthmatics
with COVID-19.
AD: atopic dermatitis; ALB: albuterol; AMC: amoxicillin/clavulanate; AR:
allergic rhinitis; AZM: azithromycin; BENRA: benralizumab; BX:
bronchiectasis; Cax: ceftriaxone; CIP: ciprofloxacin; CRSsNP: chronic
rhinosinusits without nasal polyps; CRSwNP: chronic rhinosinusitis with
nasal polyps; CVD: cardiovascular diseases; GERD: gastroesophageal
reflux disease; HCQ: hydroxychloroquine; HTN: hypertension; IBP:
ibuprofen; ICS/LABA: Inhaled corticosteroids/Long-acting beta2-agonists;
LAMA: long-acting muscarinic agents; LMWH: low molecular weight
heparins; LPV/r: lopinavir/ritonavir; LTRA: leukotriene receptor
antagonists; LVX: levofloxacin; MDD: major depressive disorder; MEPO:
mepolizumab; MV: mechanical ventilation; NIDDM: non-insulin-dependent
diabetes mellitus; NIV: non invasive ventilation; OCS: oral
corticosteroids; OMA: omalizumab; PCM: paracetamol; ;TMP-SMX:
trimethoprim/sulfamethoxazole; TOZ: tocilizumab